[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:nf2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"NF2 Gene",6,5,[8,16,23,30,36,42],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06251310","SW-682 in Advanced Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:18:38.077159Z","2026-05-05T02:43:28.970517Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04923126","SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma",[20],"Phase 1\u002FPhase 2","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:28.957186Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT02523014","Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",[27],"Phase 2","2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.482521Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT05873686","A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers",[12],"2026-08-26T02:17:00.709807Z","2026-07-19T19:36:05.121267Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04374305","Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)",[27],"2026-08-26T02:18:34.622081Z","2026-05-13T02:55:06.248563Z",{"nct_id":43,"title":44,"phases":45,"status":46,"updated_at":47,"content_modified":48},"NCT06104488","A Study of Avutometinib for People With Solid Tumor Cancers",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:10:11.726086Z","2026-05-05T02:43:26.917842Z"]